Columbus Macro LLC Buys New Holdings in Humana Inc. (NYSE:HUM)

Columbus Macro LLC bought a new position in Humana Inc. (NYSE:HUM - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 877 shares of the insurance provider's stock, valued at approximately $223,000.

Several other large investors have also recently bought and sold shares of HUM. AMF Tjanstepension AB lifted its holdings in Humana by 166.8% during the 3rd quarter. AMF Tjanstepension AB now owns 40,051 shares of the insurance provider's stock worth $12,686,000 after buying an additional 25,041 shares in the last quarter. Park Avenue Securities LLC lifted its holdings in Humana by 17.3% during the 3rd quarter. Park Avenue Securities LLC now owns 4,857 shares of the insurance provider's stock worth $1,538,000 after buying an additional 718 shares in the last quarter. Czech National Bank lifted its holdings in Humana by 6.8% during the 3rd quarter. Czech National Bank now owns 24,527 shares of the insurance provider's stock worth $7,769,000 after buying an additional 1,564 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Humana by 78.1% in the 3rd quarter. GAMMA Investing LLC now owns 1,352 shares of the insurance provider's stock valued at $428,000 after purchasing an additional 593 shares during the period. Finally, Atwood & Palmer Inc. acquired a new position in shares of Humana in the 3rd quarter valued at $29,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Bank of America raised Humana from an "underperform" rating to a "neutral" rating and increased their price target for the company from $247.00 to $308.00 in a research note on Wednesday, November 6th. Stephens reissued an "equal weight" rating and issued a $250.00 price target on shares of Humana in a research note on Wednesday, October 9th. Barclays increased their price target on Humana from $253.00 to $255.00 and gave the company an "equal weight" rating in a research note on Wednesday, January 22nd. Truist Financial increased their price target on Humana from $260.00 to $290.00 and gave the company a "hold" rating in a research note on Monday, January 6th. Finally, Piper Sandler increased their price target on Humana from $270.00 to $288.00 and gave the company a "neutral" rating in a research note on Wednesday, January 15th. Nineteen investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $297.68.

Humana Stock Down 1.7 %

HUM stock traded down $5.02 during trading hours on Wednesday, reaching $290.52. 1,102,501 shares of the stock were exchanged, compared to its average volume of 1,506,460. The company has a market cap of $34.98 billion, a price-to-earnings ratio of 25.73, a PEG ratio of 2.21 and a beta of 0.56. The firm's 50-day moving average is $275.13 and its 200-day moving average is $299.72. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of the firm's stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.29% of the stock is owned by corporate insiders.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.